Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.59) by 16.67 percent. This is a 12.5 percent increase over losses of $(0.56) per share from the same period last year.